These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
[ ]
|
Preliminary Proxy Statement
|
|
[ ]
|
Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
[x]
|
Definitive Proxy Statement |
|
[ ]
|
Definitive Additional Materials
|
|
[ ]
|
Soliciting Material Pursuant to SS.240.14a-11(c) or SS.240.14a-12
|
|
CLEARFIELD, INC.
|
|
(Name of Registrant as Specified In Its Charter)
|
|
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
|
|
[x]
|
No fee required. | |
|
[ ]
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. | |
| 1) | Title of each class of securities to which transaction applies: | |
| 2) | Aggregate number of securities to which transaction applies: | |
| 3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): | |
| 4) | Proposed maximum aggregate value of transaction: | |
| 5) | Total fee paid: | |
|
[ ]
|
Fee paid previously with preliminary materials | |
|
[ ]
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or Schedule and the date of its filing. | |
| 1) | Amount previously paid: | |
| 2) | Form, Schedule or Registration Statement No.: | |
| 3) | Filing Party: | |
| 4) | Date Filed: | |
|
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
To Be Held February 19, 2015
|
||
|
1.
|
Elect six (6) directors to serve until the next Annual Meeting of the Shareholders or until their respective successors have been elected and qualified; and
|
|
2.
|
Ratify the appointment of Baker Tilly Virchow Krause, LLP as the independent registered public accounting firm for Clearfield, Inc. for the fiscal year ending September 30, 2015.
|
|
By Order of the Board of Directors
|
|
| Ronald G. Roth | |
| Chairman of the Board of Directors | |
| January 9, 2015 |
|
WHETHER OR NOT YOU EXPECT TO ATTEND THE ANNUAL MEETING IN PERSON,
PLEASE VOTE YOUR SHARES IN ONE OF THE WAYS
DESCRIBED IN THE PROXY STATEMENT AS PROMPTLY AS POSSIBLE.
|
|
Page
|
||
|
PROXY STATEMENT
|
1
|
|
|
Solicitation of Proxies
|
1
|
|
|
Cost and Method of Solicitation
|
1
|
|
|
Voting
|
1
|
|
|
Differences Between Shareholder of Record and Beneficial Owners
|
1
|
|
|
Quorum and Voting Requirements
|
2
|
|
|
Casting Your Vote as a Record Holder
|
2
|
|
|
Casting Your Vote as a Street Name Holder
|
2
|
|
|
Revoking a Proxy
|
3
|
|
|
Annual Meeting and Special Meetings; Bylaw Amendments
|
3
|
|
|
OWNERSHIP OF VOTING SECURITIES BY PRINCIPAL HOLDERS AND MANAGEMENT
|
4
|
|
|
PROPOSAL 1: ELECTION OF DIRECTORS
|
5
|
|
|
Information Regarding Nominees
|
5
|
|
|
Vote Required for Proposal 1
|
6
|
|
|
CORPORATE GOVERNANCE
|
7
|
|
|
Board Independence
|
7
|
|
|
Committees of the Board of Directors and Committee Independence
|
7
|
|
|
Board Leadership Structure
|
8
|
|
|
Board’s Role in Risk Oversight
|
8
|
|
|
Director Nominations
|
9
|
|
|
Board Attendance at Board, Committee and Annual Shareholder Meetings
|
10
|
|
|
Communications with Directors
|
10
|
|
|
Code of Ethics
|
11
|
|
|
REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS
|
11
|
|
|
EXECUTIVE OFFICERS
|
12
|
|
|
EXECUTIVE COMPENSATION
|
12
|
|
|
Compensation Discussion and Analysis
|
12
|
|
|
Report of the Compensation Committee
|
16
|
|
|
Summary Compensation Table
|
16
|
|
|
Grants of Plan-Based Awards in Fiscal Year 2014
|
17
|
|
|
Outstanding Equity Awards at Fiscal Year-End
|
18
|
|
|
2014 Options Exercised and Stock Vested
|
19
|
|
|
Employment Arrangements with Named Executive Officers
|
19
|
|
|
Definitions of Employment Agreement and Plan Terms
|
24
|
|
|
DIRECTOR COMPENSATION
|
27
|
|
|
PROPOSAL 2: APPOINTMENT OF INDEPENDENT AUDITORS
|
28
|
|
|
Vote Required for Proposal 2
|
28
|
|
|
RELATIONSHIP WITH INDEPENDENT ACCOUNTANTS
|
28
|
|
|
Accountant Fees and Services
|
29
|
|
|
Audit Committee Pre-Approval Procedures
|
29
|
|
|
CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS
|
30
|
|
|
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
|
31
|
|
|
SHAREHOLDER PROPOSALS AND SHAREHOLDER NOMINEES FOR 2016 ANNUAL MEETING
|
31
|
|
|
OTHER BUSINESS
|
31
|
|
|
PROXY STATEMENT
|
||
|
·
|
Sending a written statement to that effect to the Secretary of Clearfield, Inc.;
|
|
·
|
Submitting a properly signed proxy card with a later date;
|
|
·
|
If you voted by telephone or through the Internet, by voting again either by telephone or through the Internet prior to the close of the voting facility; or
|
|
·
|
Voting in person at the Annual Meeting.
|
|
Name and Address of Beneficial Owner
|
Number of Shares
Beneficially Owned (1)
|
Percent of
Outstanding |
|
Ronald G. Roth (2)(3)
|
1,325,566
|
9.6%
|
|
Cheryl P. Beranek (2)(4)
|
611,272
|
4.4%
|
|
Charles N. Hayssen (2)
|
169,591
|
1.2%
|
|
Donald R. Hayward (2)
|
13,301
|
*
|
|
John G. Reddan (2)
|
35,701
|
*
|
|
Stephen L. Zuckerman, M.D. (2)
|
32,101
|
*
|
|
John P. Hill (4)
|
272,409
|
2.0%
|
|
Daniel R. Herzog (4)
|
95,074
|
*
|
|
All current executive officers and directors
as a group (8 persons)
|
2,555,015
|
18.4%
|
|
(1)
|
Includes the following number of shares that could be purchased within 60 days of December 26, 2014 upon the exercise of stock options: Mr. Roth, no shares; Ms. Beranek, 24,000 shares; Mr. Hayssen, 4,900 shares; Mr. Hayward, no shares; Mr. Reddan, 13,400 shares; Dr. Zuckerman, no shares; Mr. Hill, 24,000 shares; Mr. Herzog, 46,000 shares; and all current directors and executive officers as a group, 112,300 shares.
|
|
(2)
|
Currently serves as our director and nominated for election as a director at the Annual Meeting.
|
|
(3)
|
Includes 176,760 shares owned by Mr. Roth’s spouse.
|
|
(4)
|
Named Executive Officer.
|
|
·
|
Background, including demonstrated high personal and professional ethics and integrity;
|
|
·
|
The ability to exercise good business judgment and enhance the Board’s ability to manage and direct the affairs and business of Clearfield;
|
|
·
|
Commitment, including the willingness to devote adequate time to the work of the Board and its committees;
|
|
·
|
The ability to represent the interests of all shareholders and not a particular interest group;
|
|
·
|
The skills needed by the Board, within the context of the existing composition of the Board, including knowledge of our industry and business or experience in business, finance, law, education, research or government;
|
|
·
|
The candidate’ s qualification as “independent” under Nasdaq or other standards and qualification to serve on Board committees; and
|
|
·
|
Diversity, in terms of knowledge, experience, skills, expertise, and other demographics which contribute to the Board’s diversity.
|
|
·
|
Product inquiries, complaints or suggestions
|
|
·
|
New product suggestions
|
|
·
|
Resumes and other forms of job inquiries
|
|
·
|
Surveys
|
|
·
|
Business solicitations or advertisements
|
|
·
|
Cheryl P. Beranek, our Chief Executive Officer
|
|
·
|
Daniel R. Herzog, our Chief Financial Officer
|
|
·
|
John P. Hill, our Chief Operating Officer
|
|
·
|
Base salaries should be set at levels that recognize the significant potential compensation opportunities available through performance based compensation; and
|
|
·
|
Performance-based compensation should constitute a significant portion of the executive’s overall compensation and be available to the executive when they individually deliver, and we as a company deliver, high performance.
|
|
Name and Position
|
Year
|
Salary
($)
|
Bonus
($)(1)
|
Stock
Awards
($)(2)
|
Non-
Equity
Incentive
Plan
Compen-
sation
($)(3)
|
All
Other
Compen-
sation
($)(4)
|
Total
($)
|
|
Cheryl P. Beranek
|
2014
|
$281,689
|
$100,000
|
$561,000
|
$255,981
|
$12,373
|
$1,211,043
|
|
President and Chief
|
2013
|
263,925
|
104,112
|
—
|
395,888
|
16,060
|
779,985
|
| Executive Officer |
2012
|
263,726
|
—
|
403,155
|
200,000
|
11,564
|
878,445
|
|
Daniel R. Herzog
|
2014
|
$160,096
|
$20,000
|
$198,000
|
$48,495
|
$9,242
|
$435,833
|
|
Chief Financial Officer
|
2013
|
150,000
|
15,000
|
—
|
75,000
|
9,959
|
249,959
|
|
2012
|
149,615
|
—
|
142,290
|
40,000
|
6,697
|
338,602
|
|
|
John P. Hill
|
2014
|
$268,027
|
$80,000
|
$561,000
|
$242,475
|
$13,343
|
$1,164,845
|
|
Chief Operating Officer
|
2013
|
251,200
|
125,000
|
—
|
375,000
|
17,060
|
768,260
|
|
2012
|
248,364
|
—
|
403,155
|
185,000
|
14,047
|
850,548
|
|
(1)
|
Represents a bonus approved by the Compensation Committee as a discretionary increase to the cash bonus the named executive officer received under the cash bonus program for the fiscal year noted.
|
|
(2)
|
Represents the aggregate grant date fair value of restricted stock awards in the respective fiscal year, as computed in accordance with FASB ASC Topic 718, Compensation — Stock Compensation using the assumptions discussed in Note C, “Shareholders’ Equity,” in the notes to financial statements included in our Annual Report on Form 10-K for the year ended September 30, 2014.
|
|
(3)
|
Represents bonuses paid to the named executive officers under our cash bonus program for the year noted, which are reported for the year in which the related services were performed.
|
|
(4)
|
Represents the following amounts:
|
|
Name
|
Year
|
Matching
Contributions to
401(k) Plan
|
Travel
Benefit
(1)
|
Term Life
Insurance
Premiums (2)
|
|
2014
|
$10,768
|
$ —
|
$1,605
|
|
|
Cheryl P. Beranek
|
2013
|
10,000
|
4,455
|
1,605
|
|
2012
|
9,959
|
—
|
1,605
|
|
|
2014
|
$9,242
|
$ —
|
$—
|
|
|
Daniel R. Herzog
|
2013
|
6,908
|
3,051
|
—
|
|
2012
|
6,697
|
—
|
—
|
|
|
2014
|
$10,738
|
$ —
|
$2,605
|
|
|
John P. Hill
|
2013
|
10,000
|
4,455
|
2,605
|
|
2012
|
11,442
|
—
|
2,605
|
|
|
(1)
|
Represents amounts paid by us for travel awarded by the Compensation Committee in connection with fiscal year 2013 performance and taxes paid on behalf of the named executive officers for this benefit.
|
|
|
(2)
|
For Ms. Beranek this includes $1,605 paid by us for a term life insurance policy in each of fiscal years 2014, 2013 and 2012. The policy began January 20, 2011, provides a $2 million benefit payable to Ms. Beranek’s estate upon her death, and expires in the year 2058. For Mr. Hill, this includes $2,605 paid by us for a term life insurance policy in each of fiscal years 2014, 2013 and 2012. The policy began February 7, 2011, provides a $2 million benefit payable to Mr. Hill’s estate upon his death, and expires in the year 2061. We also have corresponding term insurance policies of each Ms. Beranek and Mr. Hill for $2 million each where the death benefit is payable to us.
|
|
Estimated Future Payouts Under
Non-Equity Incentive Plan Awards (1)
|
All Other
Stock Awards:
|
Grant Date
Fair Value of
|
||||
|
Name
|
Grant Date
|
Threshold
($)
|
Target
($)
|
Maximum
($)
|
Number of
Shares of
Stock
|
Stock and
Option
Awards (2)
|
|
Cheryl P. Beranek
|
11/21/2013
|
—
|
—
|
$423,600
|
—
|
—
|
|
Cheryl P. Beranek
|
8/21/2014
|
—
|
—
|
—
|
42,500
|
$561,000
|
|
Daniel R. Herzog
|
11/21/2013
|
—
|
—
|
$80,250
|
—
|
—
|
|
Daniel R. Herzog
|
8/21/2014
|
—
|
—
|
—
|
15,000
|
$198,000
|
|
John P. Hill
|
11/21/2013
|
—
|
—
|
$401,250
|
—
|
—
|
|
John P. Hill
|
8/21/2014
|
—
|
—
|
—
|
42,500
|
$561,000
|
|
(1)
|
Represents bonuses that could have been earned by the named executive officers under our 2014 Bonus Plan. Under the formula associated with the 2014 Bonus Plan, achievement of the performance goals at less than the maximum level will result in a decreasing bonus such that there is no “target” or “minimum” level of achievement. See the column of the Summary Compensation Table entitled “Non-Equity Incentive Plan Compensation” for the amounts actually earned under the 2014 Bonus Plan. For explanation of the 2014 Bonus Plan, refer to the description under the heading of this proxy statement entitled “Executive Compensation – Compensation Discussion and Analysis – 2014 Compensation for Named Executive Officers – Design of and Payouts Under the 2014 Bonus Plan.”
|
|
(2)
|
Represents the aggregate grant date fair value of restricted stock awards as computed in accordance with FASB ASC Topic 718, Compensation — Stock Compensation using the assumptions discussed in Note C, “Shareholders’ Equity,” in the notes to financial statements included in our Annual Report on Form 10-K for the year ended September 30, 2014.
|
|
Option Awards
|
Stock Awards
|
|||||
|
Name
|
Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
|
Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
|
Option
Exercise
Price ($)
|
Option
Expiration
Date
|
Number of
Shares of
Stock That
Have Not
Vested (#)
|
Market
Value of
Shares of
Stock That
Have Not
Vested
($)(1)
|
|
Cheryl P. Beranek (2)
|
24,000
|
6,000
|
$6.36
|
8/25/2016
|
||
|
Cheryl P. Beranek (3)
|
—
|
—
|
—
|
—
|
51,000
|
$649,230
|
|
Cheryl P. Beranek (4)
|
42,500
|
$541,025
|
||||
|
Daniel R. Herzog (5)
|
25,000
|
—
|
$3.30
|
11/20/2016
|
||
|
Daniel R. Herzog (2)
|
16,000
|
4,000
|
$6.36
|
8/25/2016
|
||
|
Daniel R. Herzog (3)
|
—
|
—
|
—
|
—
|
18,000
|
$229,140
|
|
Daniel R. Herzog (6)
|
5,000
|
—
|
$2.58
|
8/19/2020
|
||
|
Daniel R. Herzog (4)
|
15,000
|
$190,950
|
||||
|
John P. Hill (2)
|
24,000
|
6,000
|
$6.36
|
8/25/2016
|
||
|
John P. Hill (3)
|
—
|
—
|
—
|
—
|
51,000
|
$649,230
|
|
John P. Hill (4)
|
42,500
|
$541,025
|
||||
|
(1)
|
Value based on a share price of $12.73, which was the closing sales price of our common stock on The Nasdaq Stock Market on September 30, 2014, the last day of our fiscal year-end.
|
|
(2)
|
Options vest in annual installments of 20% for five years beginning August 25, 2011 with a five year term.
|
|
(3)
|
Restricted stock vests in annual installments of 20% per year for five years beginning August 23, 2013.
|
|
(4)
|
Restricted stock vests in annual installments of 10% per year for ten years beginning August 21, 2015.
|
|
(5)
|
Options vest in annual installments of 33% per year for three years beginning on November 20, 2009 with a seven year term.
|
|
(6)
|
Options vest in annual installments of 25% for four years beginning on August 19, 2011 with a ten year term.
|
|
Option Awards
|
Restricted Stock Awards
|
|||
|
Name
|
Number of
Shares
Acquired on
Exercise (#)
|
Value Realized
on Exercise
($)(1)
|
Number of Shares
Acquired on
Vesting (#)
|
Value Realized on
Vesting ($)(2)
|
|
Cheryl P. Beranek
|
225,000
|
$3,428,500
|
17,000
|
$231,370
|
|
Daniel R. Herzog
|
—
|
—
|
6,000
|
$81,660
|
|
John P. Hill
|
127,000
|
$1,910,480
|
17,000
|
$231,370
|
|
(1)
|
Represents the difference between the exercise price and the fair market value of our common stock on the respective dates of exercise.
|
|
(2)
|
Represents the fair market value of the restricted stock that vested August 23, 2014, calculated as the market price on that day multiplied by the number of shares vested.
|
|
·
|
The executive will be paid in two lump sum payments:
|
|
o
|
the executive’s earned but unpaid base salary and accrued but unpaid vacation through the date of termination and any prorated annual bonus required to be paid for the fiscal year that ends on or before the date of termination to the extent not previously paid, and
|
|
o
|
a severance amount equal to two times the sum of the executive’s annual base salary in effect of the date of termination plus average bonus over the prior three years;
|
|
·
|
The executive will receive the executive’s prorated annual bonus for the year in which the termination occurs, payable at the time bonuses are paid to the other senior executives;
|
|
·
|
We will pay premiums for the executive’s continuing coverage group health plans (medical, dental, and vision) until the earlier of one year from the date of termination or the date on which the executive is no longer eligible for such coverage;
|
|
·
|
Any unvested stock options shall become vested in full; and
|
|
·
|
We will timely pay or provide any vested benefits or other amounts or benefits required to be paid or provided that the executive is eligible to receive on the date of termination under any plan, contract or agreement.
|
|
Termination Without Cause,
For Good Reason or Non-Renewal
|
||
|
Cheryl P. Beranek
|
John P. Hill
|
|
|
Fiscal Year 2014 Bonus
|
$255,981
|
$242,475
|
|
Severance Amount
|
$1,290,216
|
$1,241,667
|
|
Value of Accelerated Vesting of Stock Options (1)
|
$38,220
|
$38,220
|
|
Insurance Premiums
|
$12,065
|
$12,065
|
|
Total
|
$1,596,482
|
$1,534,427
|
|
(1)
|
Value based on a share price of $12.73, which was the closing sales price for a share of our common stock on the Nasdaq Stock Market on September 30, 2014. Value of accelerated stock options is determined using the difference between that closing share price and the applicable option exercise price multiplied by the number of option shares whose exercisability is accelerated.
|
|
Change in Control
(Without Termination of Employment)
|
||
|
Cheryl P. Beranek
|
John P. Hill
|
|
|
Base Salary Payment
|
$282,400
|
$267,500
|
|
Value of Accelerated Vesting of Stock Options (1)
|
$38,220
|
$38,220
|
|
Value of Accelerated Lapse of Restrictions on Restricted Stock (1)
|
$1,190,255
|
$1,190,255
|
|
Total
|
$1,510,875
|
$1,495,975
|
|
(1)
|
Value based on a share price of $12.73, which was the closing sales price for a share of our common stock on the Nasdaq Stock Market on September 30, 2014. Value of accelerated stock options is determined using the difference between that closing share price and the applicable option exercise price multiplied by the number of option shares whose exercisability is accelerated. Value of accelerated lapse of restricted stock is determined by multiplying the closing share price by the number of restricted stock whose lapse of restrictions is accelerated.
|
|
Triggered by Termination Without Cause or For Good
Reason or Without Good Reason
Within 1 Year of a Change in Control
|
||
|
Cheryl P. Beranek
|
John P. Hill
|
|
|
Base Salary Payment Triggered by Change of Control
|
$282,400
|
$267,500
|
|
Fiscal Year 2014 Bonus
|
$255,981
|
$242,475
|
|
Severance Amount
|
$1,290,216
|
$1,241,667
|
|
Value of Accelerated Vesting of Stock Options (1)
|
$38,220
|
$38,220
|
|
Value of Accelerated Lapse of Restrictions on Restricted Stock (1)
|
$1,190,255
|
$1,190,255
|
|
Insurance Premiums
|
$12,065
|
$12,065
|
|
Excise Tax Reimbursement
|
$1,149,865
|
$1,141,458
|
|
Total
|
$4,219,002
|
$4,133,640
|
|
(1)
|
Value based on a share price of $12.73, which was the closing sales price for a share of our common stock on the Nasdaq Stock Market on September 30, 2014. Value of accelerated stock options is determined using the difference between that closing share price and the applicable option exercise price multiplied by the number of option shares whose exercisability is accelerated. Value of accelerated lapse of restricted stock is determined by multiplying the closing share price by the number of restricted stock whose lapse of restrictions is accelerated.
|
|
Termination By Reason of Death or Disability
|
||
|
Cheryl P. Beranek
|
John P. Hill
|
|
|
Base Salary Payment
|
$282,400
|
$267,500
|
|
Fiscal Year 2014 Bonus Payment
|
$255,981
|
$242,475
|
|
Insurance Premiums
|
$12,065
|
$12,065
|
|
Total
|
$550,446
|
$522,040
|
|
Term
|
Definition
|
|
Disability
|
A physical or mental illness which renders Executive unable to perform her/his essential duties for ninety (90) consecutive days or a total of one hundred and eighty (180) days in any twelve (12) month period with or without reasonable accommodations, or unable to perform those duties in a manner that would not endanger her/his health or safety or the health or safety of others even with reasonable accommodations.
|
|
The existence of a Disability shall be determined through the opinion (to a reasonable medical certainty) of an independent physician selected by the Company or its insurers and reasonably acceptable to the Executive or the Executive’s legal representative. The Company is not, however, required to make unreasonable accommodations for Executive or accommodations that would create an undue hardship for the Company.
|
|
|
Cause
|
(i) The Executive’s willful failure to perform or gross negligence in performing her/his duties owed to the Company (other than such failure resulting from the Executive’s Disability or any such actual failure after her/his issuance of a Notice of Termination for Good Reason), which continues after thirty (30) days following a written notice delivered to the Executive by the Board, which notice specifies such willful failure or gross negligence;
|
|
(ii) The Executive’s commission of an act of fraud or dishonesty in the performance of her/his duties;
|
|
|
(iii) The Executive’s conviction of, or entry by the Executive of a guilty or no contest plea to, any felony or a misdemeanor involving moral turpitude;
|
|
|
(iv) Any material breach by the Executive of any fiduciary duty or duty of loyalty owed to the Company; or
|
|
|
(v) The Executive’s material breach of any of the provisions of this Agreement which is not cured within thirty (30) days following written notice thereof from the Company.
|
|
|
Good Reason
|
The occurrence of any one or more of the following events without the Executive’s prior written consent, provided that the Executive terminates her/his employment within one hundred and eighty (180) days following the lapse of the Company’s cure period described below as to one or more of such events and unless the Company fully corrects the circumstances constituting Good Reason (provided such circumstances are capable of correction) prior to the Date of Termination:
|
|
(i) The Company’s reduction of the Executive’s annual base salary below the initial Base Salary or reduction in the Executive’s target annual bonus;
|
|
|
(ii) The Company’s material change of the Executive’s duties in a manner inconsistent with the Executive’s position, authority, duties or responsibilities as contemplated by Section 2(a) or other action by the Company which materially diminishes such position, authority, duties or responsibilities, excluding for this purpose isolated, insubstantial or inadvertent action not taken in bad faith and which is remedied by the Company promptly after receipt of notice thereof from Executive;
|
|
|
(iii) The relocation of the Company’s offices at which Executive is principally employed to a location more than 50 miles from such offices;
|
|
|
(iv) The failure of a successor to the Company to (A) assume and agree to perform the obligations of the Company hereunder, or (B) replace this Agreement with an employment contract of substantially similar terms acceptable to the Executive and no less favorable than those terms provided to an acquiring Company’s executive officers; or
|
|
Term
|
Definition
|
|
(v) The Company’s material breach of its obligations under the Agreement.
|
|
|
Notwithstanding any other provision of this Section 3(e), the occurrence of any event described in Section 3(e)(i) or (v) shall constitute Good Reason only if (A) the Executive provides written notice to the Company of the occurrence of such event within ninety (90) days of the initial occurrence of such event, and (B) the Company fails to remedy the event described in the Executive’s written notice within thirty (30) days of the Company’s receipt of such notice.
|
|
|
Change in Control
|
Change in Control as defined in the Company’s 2007 Stock Compensation Plan as in effect on December 16, 2008, but excluding from such definition Section 8(b)(ii) thereof, which means the happening of any of the following:
|
|
(i) A majority of the directors of the Company shall be persons other than persons
|
|
|
(A) For whose election proxies shall have been solicited by the Board, or
|
|
|
(B) Who are then serving as directors appointed by the Board to fill vacancies on the Board caused by death or resignation (but not by removal) or to fill newly-created directorships,
|
|
|
(iii) The shareholders of the Company approve a definitive agreement or plan to
|
|
|
(A) Merge or consolidate the Company with or into another corporation other than
|
|
|
(1) a merger or consolidation with a subsidiary of the Company or
|
|
|
(2) a merger in which
|
|
|
(a) the Company is the surviving corporation,
|
|
|
(b) no outstanding voting stock of the Company (other than fractional shares) held by shareholders immediately prior to the merger is converted into cash, securities, or other property (except (i) voting stock of a parent corporation owning directly, or indirectly through wholly owned subsidiaries, both beneficially and of record 100% of the voting stock of the Company immediately after the merger and (ii) cash upon the exercise by holders of voting stock of the Company of statutory dissenters' rights),
|
|
|
(c) the persons who were the beneficial owners, respectively, of the outstanding common stock and outstanding voting stock of the Company immediately prior to such merger beneficially own, directly or indirectly, immediately after the merger, more than 70% of, respectively, the then outstanding common stock and the then outstanding voting stock of the surviving corporation or its parent corporation, and
|
|
|
(d) if voting stock of the parent corporation is exchanged for voting stock of the Company in the merger, all holders of any class or series of voting stock of the Company immediately prior to the merger have the right to receive substantially the same per share consideration in exchange for their voting stock of the Company as all other holders of such class or series,
|
|
|
(B) exchange, pursuant to a statutory exchange of shares of voting stock of the Company held by shareholders of the Company immediately prior to the exchange, shares of one or more classes or series of voting stock of the Company for cash, securities, or other property,
|
|
|
(C) sell or otherwise dispose of all or substantially all of the assets of the Company (in one transaction or a series of transactions), or
|
|
|
(D) liquidate or dissolve the Company.
|
|
Name
|
Fees Earned or Paid
in Cash
($) (1)
|
Restricted Stock
Awards
($) (2)
|
Total
($)
|
|
Ronald G. Roth
|
$10,000
|
$9,992
|
$19,992
|
|
Charles N. Hayssen
|
12,500
|
9,992
|
22,492
|
|
Donald R. Hayward
|
10,000
|
9,992
|
19,992
|
|
John G. Reddan
|
10,000
|
9,992
|
19,992
|
|
Stephen L. Zuckerman, M.D.
|
10,000
|
9,992
|
19,992
|
|
(1)
|
Represents cash retainer for fiscal year 2014 as described above.
|
|
(2)
|
Represents the aggregate grant date fair value of the restricted stock award described above, computed in accordance with FASB ASC Topic 718, Compensation — Stock Compensation. The fair value of the restricted stock award is determined as the average price of our stock on the date of grant as discussed in Note C, “Shareholders’ Equity,” in the notes to financial statements included in our Annual Report on Form 10-K for the year ended September 30, 2014.
|
|
Baker Tilly Virchow
Krause, LLP 2014
|
Grant Thornton LLP
2014
|
Grant Thornton LLP
2013
|
|
|
Audit Fees
|
$131,665
|
$25,000
|
$150,620
|
|
Audit-Related Fees
|
1,580
|
–
|
–
|
|
Tax Fees
|
–
|
–
|
14,241
|
|
All Other Fees
|
6,755
|
–
|
–
|
|
Total Fees
|
$140,000
|
$25,000
|
$164,861
|
|
·
|
employment of executive officers and director compensation to be reported in our proxy statement;
|
|
·
|
ordinary course business travel and expenses, advances and reimbursements;
|
|
·
|
payments made under our articles of incorporation, bylaws, insurance policies or other agreements relating to indemnification
|
|
·
|
any transaction with another company where the related party is an employee, director or beneficial owner of that other company, if the aggregate amount involved does not exceed $50,000;
|
|
·
|
transactions in which our shareholders receive proportional benefits; and
|
|
·
|
regulated transactions at rates or charges fixed in conformity with law or governmental authority and transactions involving certain banking related services.
|
|
·
|
whether the terms are fair to us;
|
|
·
|
whether the terms of the related party transaction are no less favorable than terms generally available to an unaffiliated third-party under the same or similar circumstances;
|
|
·
|
whether the related party transaction is material to us;
|
|
·
|
the role the related party has played in arranging the transaction;
|
|
·
|
the structure of the related party transaction;
|
|
·
|
the interests of all related parties in the transaction;
|
|
·
|
the extent of the related party’s interest in the transaction; and
|
|
·
|
whether the transaction would require a waiver of our Code of Ethics and Business Conduct.
|
| By Order of the Board of Directors | |
| Ronald G. Roth | |
| Chairman of the Board of Directors |
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|